Tubal passage control after methotrexate treatment in ectopic pregnancies

• Published in: Journal of clinical and experimental investigations Vol. 2; no. 4; p. 400
• Main Authors: Görük, Neval Yaman, Turgut, Abdulkadir, Tunç, Senem Yaman, Süer, Necdet
• Format: Journal Article
• Language: English
• Published: East Sussex 12.12.2011
• Subjects: Pregnancy complications
• ISSN: 1309-6621; 1309-6621
• DOI: 10.5799/ahinjs.01.2011.04.0080

Objectives: In this study, it was aimed to evaluate the results of ipsilateral tubal passage control in the cases treated with methotrexate (MTX). Materials and methods: Totally 30 patients aged between 21 and 40 years who have received single dose MTX treatment due to ectopic pregnancy was included. All patients were as hemodynamically stabile. Serum beta human chorionic gonadotropin (BhCG) levels and ultrasonographic findings prior to the MTX treatment were recorded. Patients were re-evaluated 6 months after serum BhCG levels became negative for the outcome of treatment. Results: The mean age of the 30 cases was 30.6±4.4 years. The BhCG levels of the cases was changing between 160 and 10910, their average is 2387±2499 IU/L. The MTX dose was changing between 50 to 100 mg, with average of 67.7±13.5 mg. Four (13.3%) of the cases received additional dose of MTX. Laparotomy was performed in 3 (10%) cases due to tubal rupture developing during the treatment. Among 27 cases on whom the tubal passage control is made 6 months after the treatment, tubal passage was found to be open in 22 (81.5%) of the cases and closed in 5 (18.5%). There was no significant difference between the BhCG levels of cases with open and closed tubal passage (p>0.05). Conclusion: The medical treatment to be applied on non-ruptured ectopic pregnancies has many advantages. Less tubal damage occurs by the medical treatment, it decreases the morbidity for anesthesia and surgery.